Epigenetics of hematopoiesis and hematological malignancies
Open accessThe DOI matches its Crossref record; 251 of the 251 references it cites were found in a registry or an index.
Abstract
Hematological malignancies comprise a diverse set of lymphoid and myeloid neoplasms in which normal hematopoiesis has gone awry and together account for ∼10% of all new cancer cases diagnosed in the United States in 2016. Recent intensive genomic sequencing of hematopoietic malignancies has identified recurrent mutations in genes that encode regulators of chromatin structure and function, highlighting the central role that aberrant epigenetic regulation plays in the pathogenesis of these neoplasms. Deciphering the molecular mechanisms for how alterations in epigenetic modifiers, specifically histone and DNA methylases and demethylases, drive hematopoietic cancer could provide new avenues for developing novel targeted epigenetic therapies for treating hematological malignancies. Just as past studies of blood cancers led to pioneering discoveries relevant to other cancers, determining the contribution of epigenetic modifiers in hematologic cancers could also have a broader impact on our understanding of the pathogenesis of solid tumors in which these factors are mutated.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Items 201–251 of 251
The Histone Methyltransferase Activity of MLL1 Is Dispensable for Hematopoiesis and Leukemogenesis
Mishra, B. P., Zaffuto, K. M., Artinger, E. L., Org, T., Mikkola, H. K. A., Cheng, C., Djabali, M., & Ernst, P. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.04.015 · Cited by 151 · cited 1×
“Furthermore, mouse genetic studies have demonstrated that the SET domain of the wildtype copy of MLL is dispensable for leukemogenesis (Mishra et al. 2014), raising the question of the efficacy of targeting the wild-type copy of MLL for treating MLL chimera-driven leukemia.”
BackgroundEarly mammalian erythropoiesis requires the Dot1L methyltransferase
Feng, Y., Yang, Y., Ortega, M. M., Copeland, J. N., Zhang, M., Jacob, J. B., Fields, T. A., Vivian, J. L., & Fields, P. E. (2010) · Blood · doi:10.1182/blood-2010-03-276501 · Cited by 149 · cited 1×
“5 and display a severe anemia due to reduced expression of the erythroid master regulator Gata2 (Feng et al. 2010).”
BackgroundExploiting the Epigenome to Control Cancer-Promoting Gene-Expression Programs
Brien, G. L., Valerio, D. G., & Armstrong, S. A. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.03.007 · Cited by 145 · cited 1×
“Indeed, inhibitors targeting chromatin-modifying enzymes are being used in clinical trials (Cai et al. 2015; Brien et al. 2016).”
MethodLi, X., González, M. E., Toy, K. A., Filzen, T. M., Merajver, S. D., & Kleer, C. G. (2009) · American Journal Of Pathology · doi:10.2353/ajpath.2009.090042 · Cited by 140
Polyhomeotic has a tumor suppressor activity mediated by repression of Notch signaling
Martinez, A., Schuettengruber, B., Sakr, S., Janic, A., González, C., & Cavalli, G. (2009) · Nature Genetics · doi:10.1038/ng.414 · Cited by 140 · cited 1×
“Aberrant up-regulation of NSD2 and a subsequent increase of H3K36me2 lead to an altered localization and overall decrease in the levels of H3K27me3 (Kuo et al. 2011; Martinez-Garcia et al. 2011; Popovic et al. 2014).”
BackgroundMochizuki-Kashio, M., Aoyama, K., Sashida, G., Oshima, M., Tomioka, T., Muto, T., Wang, C., & Iwama, A. (2015) · Blood · doi:10.1182/blood-2015-03-634428 · Cited by 137
Opposing roles of polycomb repressive complexes in hematopoietic stem and progenitor cells
Majewski, I. J., Ritchie, M. E., Phipson, B., Corbin, J., Pakusch, M., Ebert, A., Busslinger, M., Koseki, H., Hu, Y., Smyth, G. K., et al. (2010) · Blood · doi:10.1182/blood-2009-12-260760 · Cited by 135 · cited 1×
“Several studies have shown that PRC2 restricts HSC activity, as a partial loss of the core components such as Ezh2, Eed, or Suz12 inmice enhances HSC function (Majewski et al. 2008, 2010).”
BackgroundMohty, M., Yong, A. S. M., Szydlo, R. M., Apperley, J. F., & Melo, J. V. (2007) · Blood · doi:10.1182/blood-2006-12-065599 · Cited by 135 · cited 2×
“However, overexpression of BMI1, an integral subunit that stimulates the ubiquitinase activity of PRC1 toward H2AK119, has been observed in myeloid malignancies and has emerged as a useful indicator for the prognosis of MDS, CMML, and AML (Mihara et al. 2006; Chowdhury et al. 2007; Mohty et al. 2007).”
BackgroundMutational spectrum of adult T-ALL
Neumann, M., Vosberg, S., Schlee, C., Heesch, S., Schwartz, S., Gökbuget, N., Hoelzer, D. F., Graf, A., Krebs, S., Bartram, I., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2218 · Cited by 135 · cited 1×
“MLL4 (GeneID 8085) mutations are prevalent in NHL (Morin et al. 2011; Pasqualucci et al. 2011; Lohr et al. 2012; Green et al. 2015), ALL (Mar et al. 2012; Lindqvist et al. 2015; Neumann et al. 2015), and AML (Kandoth et al. 2013).”
BackgroundTürkmen, S., Gillessen‐Kaesbach, G., Meinecke, P., Albrecht, B., Neumann, L. M., Hesse, V., Palanduz, Ş., Balg, S., Majewski, F., Fuchs, S., et al. (2003) · European Journal of Human Genetics · doi:10.1038/sj.ejhg.5201050 · Cited by 132 · cited 1×
“4A; Valinluck and Sowers 2007; Hashimoto et al. 2012).”
BackgroundPolycomb Repressive Complex 2 (PRC2) Restricts Hematopoietic Stem Cell Activity
Majewski, I. J., Blewitt, M. E., de Graaf, C. A., McManus, E. J., Bahlo, M., Hilton, A. A., Hyland, C. D., Smyth, G. K., Corbin, J. E., Metcalf, D., et al. (2008) · PLoS Biology · doi:10.1371/journal.pbio.0060093 · Cited by 131 · cited 1×
“Several studies have shown that PRC2 restricts HSC activity, as a partial loss of the core components such as Ezh2, Eed, or Suz12 inmice enhances HSC function (Majewski et al. 2008, 2010).”
BackgroundMihara, K., Chowdhury, M., Nakaju, N., Hidani, S., Ihara, A., Hyodo, H., Yasunaga, S., Takihara, Y., & Kimura, A. (2006) · Blood · doi:10.1182/blood-2005-06-2393 · Cited by 130 · cited 1×
“This complex harbors methyltransferase activity specifically toward Lys4 of histone H3 (Miller et al. 2001; Krogan et al. 2002; Shilatifard 2012; Piunti and Shilatifard 2016).”
BackgroundBenyoucef, A., Palii, C. G., Wang, C., Porter, C. J., Chu, A., Dai, F., Tremblay, V., Rakopoulos, P., Singh, K., Huang, S., et al. (2016) · Genes & Development · doi:10.1101/gad.276790.115 · Cited by 125 · cited 1×
“More recent studies found that UTX can also act as an oncogene in TAL1-positive T-ALL, while UTX can inhibit cell growth when overexpressed in TAL1-negative T-ALL cells (Benyoucef et al. 2016).”
BackgroundAkasaka, T., Tsuji, K., Kawahira, H., Kanno, M., Harigaya, K., Hu, L., Ebihara, Y., Nakahata, T., Tetsu, O., Taniguchi, M., et al. (1997) · Immunity · doi:10.1016/s1074-7613(00)80516-6 · Cited by 124 · cited 1×
“However, Mel18 was demonstrated to have important roles in the proliferation and maturation of B cells, indicating a function in lymphoid differentiation (Akasaka et al. 1997; Tetsu et al. 1998).”
BackgroundThe polycomb repressive complex 2 governs life and death of peripheral T cells
Zhang, Y., Kinkel, S., Maksimovic, J., Bandala-Sanchez, E., Tanzer, M. C., Naselli, G., Zhang, J.-G., Zhan, Y., Lew, A. M., Silke, J., et al. (2014) · Blood · doi:10.1182/blood-2013-12-544106 · Cited by 115
Steidl, U., Steidl, C., Ebralidze, A., Chapuy, B., Han, H.-J., Will, B., Rosenbauer, F., Becker, A., Wagner, K., Koschmieder, S., et al. (2007) · Journal of Clinical Investigation · doi:10.1172/jci30525 · Cited by 114
Insertion of c- Myc into Igh Induces B-Cell and Plasma-Cell Neoplasms in Mice
Park, S. S., Kim, J. S., Tessarollo, L., Owens, J. D., Peng, L., Han, S. S., Tae Chung, S., Torrey, T. A., Cheung, W. C., Polakiewicz, R. D., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-0268 · Cited by 113 · cited 1×
“…is the chromosomal translocation commonly found in Burkitt’s lymphoma that places theMYC oncogene under the control of an immunoglobulin heavy chain (Igh) enhancer, leading to the uncontrolled expression of MYC and the development of lymphoma (Dalla-Favera et al. 1982; Park et al. 2005).”
BackgroundHematopoietic Stem Cell Development
Cullen, S. M., Mayle, A., Rossi, L., & Goodell, M. A. (2014) · Current topics in developmental biology/Current Topics in Developmental Biology · doi:10.1016/b978-0-12-416022-4.00002-0 · Cited by 109 · cited 2×
“1A; Moore and Metcalf 1970; Lux et al. 2008; Orkin and Zon 2008; Baron et al. 2012; Cullen et al. 2014).”
BackgroundHerrera-Merchan, A., Arranz, L., Ligos, J. M., de Molina, A., Dominguez, O., & Gonzalez, S. (2017) · Nature Communications · doi:10.1038/ncomms14005 · Cited by 108
Kajiume, T., Ninomiya, Y., Ishihara, H., Kanno, R., & Kanno, M. (2004) · Experimental Hematology · doi:10.1016/j.exphem.2004.03.001 · Cited by 106 · cited 1×
“Although homologous to Bmi1, Mel18 loss has very little impact on the repopulating capacity of fetal HSCs, with the self-renewing capacity of adult HSCs being enhanced in the absence of Mel18, suggesting that Bmi1 and Mel18 have distinct functions in HSCs (Iwama et al. 2004; Kajiume et al. 2004).”
BackgroundLee, S. C. W., Miller, S., Hyland, C., Kauppi, M., Lebois, M., Di Rago, L., Metcalf, D., Kinkel, S. A., Josefsson, E. C., Blewitt, M. E., et al. (2015) · Blood · doi:10.1182/blood-2014-12-615898 · Cited by 105 · cited 2×
“Homozygous deletion of Suz12 also results in failures in both embryonic and adult hematopoiesis (Lee et al. 2015).”
BackgroundFactors regulating the transcriptional elongation activity of RNA polymerase II
Shilatifard, A. (1998) · The FASEB Journal · doi:10.1096/fasebj.12.14.1437 · Cited by 104 · cited 4×
“MLL3 and MLL4 (KMT2C and KMT2D) comprise one of the three major branches of the COMPASS family in mammals, with the other two major branches represented by MLL/MLL2 (KMT2A/ KMT2B) and SET1A/SET1B (Mohan et al. 2011; Herz et al. 2012; Shilatifard 2012).”
BackgroundInfluentialSelf-citationChowdhury, M., Mihara, K., Yasunaga, S., Ohtaki, M., Takihara, Y., & Kimura, A. (2007) · Leukemia · doi:10.1038/sj.leu.2404623 · Cited by 99 · cited 1×
“…overexpression of BMI1, an integral subunit that stimulates the ubiquitinase activity of PRC1 toward H2AK119, has been observed in myeloid malignancies and has emerged as a useful indicator for the prognosis of MDS, CMML, and AML (Mihara et al. 2006; Chowdhury et al. 2007; Mohty et al. 2007).”
BackgroundBerg, T., Thoene, S., Yap, D., Wee, T., Schoeler, N., Rosten, P., Lim, E. L., Bilenky, M., Mungall, A. J. J., Oellerich, T., et al. (2014) · Blood · doi:10.1182/blood-2012-12-473439 · Cited by 96 · cited 2×
“Transgenic mouse models initially demonstrated that a specific overexpression of EZH2 in lymphocytes is insufficient for lymphomagenesis on its own but can cooperate with Bcl2 or Myc overexpression (Beguelin et al. 2013; Berg et al. 2014).”
BackgroundCalés, C., Román-Trufero, M., Pavón, L., Serrano, I., Melgar, T., Endoh, M., Pérez, C., Koseki, H., & Vidal, M. (2008) · Molecular and Cellular Biology · doi:10.1128/mcb.01136-07 · Cited by 95 · cited 1×
“Conditional deletion of Ring1b in adult hematopoietic lineages revealed its restrictive role in the proliferation of hematopoietic stem and progenitor cells and its favorable function in the proliferation of differentiated progenies (Cales et al. 2008).”
BackgroundPiunti, A., Rossi, A., Cerutti, A., Albert, M., Jammula, S., Scelfo, A., Cedrone, L., Fragola, G., Olsson, L., Koseki, H., et al. (2014) · Nature Communications · doi:10.1038/ncomms4649 · Cited by 93 · cited 1×
“In vitro studies revealed that HSCs with a deletion of both Ring1a and Ring1b show a severe defect in their self-renewing capacity (Piunti et al. 2014).”
BackgroundThe Little Elongation Complex Regulates Small Nuclear RNA Transcription
Smith, E. R., Lin, C., Garrett, A. S., Thornton, J., Mohaghegh, N., Hu, D., Jackson, J., Saraf, A., Swanson, S. K., Seidel, C., et al. (2011) · Molecular Cell · doi:10.1016/j.molcel.2011.12.008 · Cited by 91 · cited 3×
“However, a more recent study with the Y641F mutation knocked in the endogenous Ezh2 locus in mice showed that Ezh2Y641F itself could cause development of lymphoma and melanoma (Souroullas et al. 2016).”
BackgroundSelf-citationNSD2 Is Recruited through Its PHD Domain to Oncogenic Gene Loci to Drive Multiple Myeloma
Huang, Z., Wu, H., Chuai, S., Xu, F., Yan, F., Englund, N. P., Wang, Z., Zhang, H., Fang, M., Wang, Y., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-1000 · Cited by 83 · cited 2×
“Interestingly, studies demonstrated that TET1 is overexpressed in MLL-rearranged leukemia and that TET1 function is required for up-regulating the expression of MLL chimera oncogenic targets such as HOXA9, MEIS1, and PBX3 (Huang et al. 2013a).”
BackgroundSequencing histone-modifying enzymes identifies UTX mutations in acute lymphoblastic leukemia
Mar, B. G., Bullinger, L., Basu, E., Schlis, K., Silverman, L. B., Döhner, K., & Armstrong, S. A. (2012) · Leukemia · doi:10.1038/leu.2012.56 · Cited by 77 · cited 2×
“PcG proteins operate in at least two distinct multiprotein complexes, PRC1 and PRC2; each harbors an enzymatic activity, with PRC1 implementing H2AK119 monoubiquitination, and PRC2 implementingH3K27methylation (Margueron and Reinberg 2011).”
BackgroundHu, D., Smith, E. R., Garruss, A. S., Mohaghegh, N., Varberg, J. M., Lin, C., Jackson, J., Gao, X., Saraf, A., Florens, L., et al. (2013) · Molecular Cell · doi:10.1016/j.molcel.2013.07.003 · Cited by 72 · cited 2×
“3A; Herz et al. 2012, 2014; Hu et al. 2013a).”
BackgroundSelf-citationTranscriptional elongation checkpoint control in development and disease
Smith, E. R., & Shilatifard, A. (2013) · Genes & Development · doi:10.1101/gad.215137.113 · Cited by 72 · cited 3×
“Further studies by other laboratories have now confirmed these original findings establishing MLL3 and MLL4 COMPASS as major regulators of enhancer H3K4 function (Kanda et al. 2013; Lee et al. 2013; Smith and Shilatifard 2014).”
BackgroundResultSelf-citationDevelopmentally induced Mll1 loss reveals defects in postnatal haematopoiesis
Gan, T., Jude, C. D., Zaffuto, K. M., & Ernst, P. (2010) · Leukemia · doi:10.1038/leu.2010.171 · Cited by 71 · cited 2×
“a fatal bonemarrow failure occurring at∼3 wk of age (Jude et al. 2007; Gan et al. 2010).”
BackgroundRecent progress toward epigenetic therapies: the example of mixed lineage leukemia
Neff, T., & Armstrong, S. A. (2013) · Blood · doi:10.1182/blood-2013-02-474833 · Cited by 71
Tetsu, O., Ishihara, H., Kanno, R., Kamiyasu, M., Inoue, H., Tokuhisa, T., Taniguchi, M., & Kanno, M. (1998) · Immunity · doi:10.1016/s1074-7613(00)80627-5 · Cited by 70 · cited 2×
“DNA methylation is dynamically regulated during hematopoietic differentiation, and each DNA methyltransferase plays crucial roles in physiological hematopoiesis (Tadokoro et al. 2007; Broske et al. 2009; Trowbridge et al. 2009; Ji et al. 2010; Bock et al. 2012; Challen et al. 2012).”
BackgroundZebrafish as a Model for the Study of Human Cancer
Etchin, J., Kanki, J. P., & Look, A. T. (2011) · Methods in cell biology · doi:10.1016/b978-0-12-381320-6.00013-8 · Cited by 70 · cited 1×
“In addition to the mouse models of these cancers, hematological cancers are also being modeled in zebrafish (Etchin et al. 2011).”
BackgroundUveal melanoma cells are resistant to EZH2 inhibition regardless of BAP1 status
Schoumacher, M., Corre, S. L., Houy, A., Mulugeta, E., Stern, M., Roman‐Roman, S., & Margueron, R. (2016) · Nature Medicine · doi:10.1038/nm.4098 · Cited by 67
Frequency of NUP98-NSD1 fusion transcript in childhood acute myeloid leukaemia
Cerveira, N., Correia, C., Dória, S., Bizarro, S., Rocha, P., Gomes, P., Torres, L. M. M., Norton, L., Borges, B. S., Castedo, S. M. M. J., et al. (2003) · Leukemia · doi:10.1038/sj.leu.2403104 · Cited by 67 · cited 1×
“5) chromosomal translocation fuses NSD1 to nucleoporin98 (NUP98) to generate a NUP98–NSD1 chimera in 5% of human AMLs (Cerveira et al. 2003).”
BackgroundDanis, E. P., Yamauchi, T., Echanique, K. A., Zhang, X., Haladyna, J. N., Riedel, S. S., Zhu, N., Xie, H., Orkin, S. H., Armstrong, S. A., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.01.064 · Cited by 66 · cited 3×
“Conditional loss of Ezh2 in a hematopoietic system contributes to the pathogenesis of MDS and accelerates the onset of the early T-cell precursor ALL (ETPALL) induced by oncogenic NRAS (Score et al. 2012; Muto et al. 2013; Danis et al. 2016).”
Backgroundvan den Boom, V., Geugien, M., Bonardi, F., Malanga, D., van Gosliga, D., Heijink, A. M., Viglietto, G., Morrone, G., Fusetti, F., Vellenga, E., et al. (2013) · Blood · doi:10.1182/blood-2012-08-451666 · Cited by 65
The role of mutations in epigenetic regulators in myeloid malignancies
Woods, B. A., & Levine, R. L. (2015) · Immunological Reviews · doi:10.1111/imr.12246 · Cited by 60 · cited 1×
“EZH2 is the most frequently mutated PcG member in the pathogenesis of hematological malignancies (Kroeze et al. 2012;Woods and Levine 2015).”
BackgroundMyeloproliferative neoplasms: Current molecular biology and genetics
Saeidi, K. (2015) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2015.11.004 · Cited by 59 · cited 1×
“MPNs is a group of diseases characterized by the overproduction of one or more blood cell types in the bonemarrowand circulating blood (Saeidi 2016).”
BackgroundDrugging Chromatin in Cancer: Recent Advances and Novel Approaches
Cai, S. F., Chen, C.-W. D., & Armstrong, S. A. (2015) · Molecular Cell · doi:10.1016/j.molcel.2015.10.042 · Cited by 58 · cited 3×
“Indeed, inhibitors targeting chromatin-modifying enzymes are being used in clinical trials (Cai et al. 2015; Brien et al. 2016).”
BackgroundMethodTaketani, T., Taki, T., Nakamura, H., Taniwaki, M., Masuda, J., & Hayashi, Y. (2009) · Cancer Genetics and Cytogenetics · doi:10.1016/j.cancergencyto.2008.12.008 · Cited by 55 · cited 1×
“3C; Gao et al. 2012; Tavares et al. 2012; Aranda et al. 2015; Piunti and Shilatifard 2016).”
BackgroundMLL partial tandem duplication leukemia cells are sensitive to small molecule DOT1L inhibition
Kühn, M. W. M., Hadler, M., Daigle, S. R., Koche, R. P., Krivtsov, A. V., Olhava, E. J., Caligiuri, M. A., Huang, G., Bradner, J. E., Pollock, R. M., et al. (2015) · Haematologica · doi:10.3324/haematol.2014.115337 · Cited by 54 · cited 1×
“A recent study showed that leukemia cells with MLL-PTD are sensitive to DOT1L small molecule inhibition by EPZ-5676, although the oncogenic mechanisms of MLL-PTDmay differ from that of MLL chimeras (Kuhn et al. 2015).”
BackgroundLindqvist, C. M., Nordlund, J., Ekman, D. S., Johansson, A., Moghadam, B. T., Raine, A., Övernäs, E., Dahlberg, J., Wahlberg, P., Henriksson, N., et al. (2014) · Human Mutation · doi:10.1002/humu.22719 · Cited by 53 · cited 20×
“(D) Inactivating mutations in MLL3, MLL4, UTX, and EZH2 were observed in myeloid leukemias (MDS, chronic myelomonocytic leukemia [CMML], and primary myelofibrosis [PMF]) and T-cell ALL (TALL).”
BackgroundInfluentialKanda, H., Nguyen, A., Chen, L., Okano, H., & Hariharan, I. K. (2013) · Molecular and Cellular Biology · doi:10.1128/mcb.01585-12 · Cited by 52 · cited 1×
“Further studies by other laboratories have now confirmed these original findings establishing MLL3 and MLL4 COMPASS as major regulators of enhancer H3K4 function (Kanda et al. 2013; Lee et al. 2013; Smith and Shilatifard 2014).”
ResultAndersen, E., Carey, J. C., Earl, D., Corzo, D., Suttie, M., Hammond, P., & South, S. T. (2013) · European Journal of Human Genetics · doi:10.1038/ejhg.2013.192 · Cited by 46 · cited 1×
“The NSD2 gene is among a group of genes deleted inWolf-Hirschhorn syndrome, and loss of NSD2 is thought to be responsible for a subset of the clinical features characteristic of this syndrome (Andersen et al. 2014).”
BackgroundMutations galore in myeloproliferative neoplasms: Would the real Spartacus please stand up?
Tefferi, A. (2011) · Leukemia · doi:10.1038/leu.2011.92 · Cited by 32
Polycomb Group Protein Bmi1 Promotes Hematopoietic Cell Development from Embryonic Stem Cells
Ding, X., Lin, Q., Enseñat‐Waser, R., Rose‐John, S., & Zenke, M. (2011) · Stem Cells and Development · doi:10.1089/scd.2010.0539 · Cited by 28 · cited 1×
“Ectopic expression of Bmi1 in mouse embryonic stem cells has been shown to promote primitive hematopoiesis (Ding et al. 2012).”
BackgroundGenetic defects in PRC2 components other than EZH2 are not common in myeloid malignancies
Kroeze, L. I., Nikoloski, G., da Silva-Coelho, P., van Hoogen, P., Stevens-Linders, E., Kuiper, R. P., Schnittger, S., Haferlach, T., Pahl, H. L., van der Reijden, B. A., et al. (2012) · Blood · doi:10.1182/blood-2011-07-365213 · Cited by 19 · cited 1×
“EZH2 is the most frequently mutated PcG member in the pathogenesis of hematological malignancies (Kroeze et al. 2012;Woods and Levine 2015).”
BackgroundReply to "Uveal melanoma cells are resistant to EZH2 inhibition regardless of BAP1 status"
LaFave, L. M., Béguelin, W., Koche, R. P., Teater, M. R., Spitzer, B. G., Chramiec, A. G., Papalexi, E., Keller, M. D., Hricik, T., Konstantinoff, K., et al. (2016) · Nature Medicine · doi:10.1038/nm.4094 · Cited by 10 · cited 1×
“EZH2 dependence for BAP1 mutant malignancies appears to be context-dependent, as BAP1 mutant uveal melanoma cells do not exhibit sensitivity toward EZH2 inhibition, which is in contrast to findings observed in hematopoietic and mesothelioma cells (LaFave et al. 2016; Schoumacher et al. 2016).”
Result
Cited by
Mechanisms that regulate the activities of TET proteins
Joshi, K., Liu, S., Breslin S.J., P., & Zhang, J. (2022) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-022-04396-x · Cited by 162
Automated in situ chromatin profiling efficiently resolves cell types and gene regulatory programs
Janssens, D. H., Wu, S. J., Sarthy, J. F., Meers, M. P., Myers, C. H., Olson, J. M., Ahmad, K., & Henikoff, S. (2018) · Epigenetics & Chromatin · doi:10.1186/s13072-018-0243-8 · Cited by 73
Polycomb repressive complexes in hematological malignancies
Iwama, A. (2017) · Blood · doi:10.1182/blood-2017-02-739490 · Cited by 55
SALL Proteins; Common and Antagonistic Roles in Cancer
Álvarez, C., Quiroz, A., Benítez-Riquelme, D., Riffo, E., Castro, A. F., & Pincheira, R. (2021) · Cancers · doi:10.3390/cancers13246292 · Cited by 37
Metadata
- Authors
- Hu, D., & Shilatifard, A.
- Venue
- Genes & Development
- Publisher
- Cold Spring Harbor Laboratory
- Published
- 2016-09-15
- Volume
- 30
- Issue
- 18
- Pages
- 2021-2041
- ISSN
- 0890-9369 (ISSN-L)
- 1549-5477
- OpenAlex
- W2529821441
- Cited by
- 168
- References
- 251
- Type
- posted content
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.